Partnerships are key to Starpharma's business and offer significant optionality. Our partnerships involve leveraging our proprietary dendrimer technology platform to develop and commercialise innovative products to meet significant clinical needs and create value for all stakeholders.
Starpharma has a deep intellectual property portfolio with more than 200 granted patents and invests in research and development activities to expand the applications of its dendrimer platform and develop new products. In parallel, Starpharma collaborates with leading pharmaceutical and life science companies to develop and commercialise their products, leveraging our dendrimer technology. These partner-funded collaborations typically involve joint research and sharing of expertise, with partners granted access to Starpharma’s DEP® platform to apply to their programs, progress their product development, and overcome barriers such as poor solubility, narrow therapeutic index or sub-optimal pharmacokinetics.